Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

Historically, commercial use of university research has been viewed in terms of spillovers. Recently, there has been a dramatic increase in technology transfer through licensing as universities attempt to appropriate the returns from faculty research. This change has prompted concerns regarding the source of this growth—specifically, whether it suggests a change in the nature of university research. (Thursby 2002) ^ University-based firms are receiving growing interest from policy makers and researchers. Such firms obtain a variety of tangible and intangible resources from their academic partners, and are expected to translate these advantages into substantial gains. (Bonardo 2011) ^Technology transfer is a big concern for universities, how can they identify business opportunities from IP developed? We have created relationships with universities to help them do just that. Contact us to learn more.

Understanding the growing "Intermediary" landscape is essential for your development of in/out strategies. Whether you are looking to buy/sell, license, identify potential infringement/infringees, expand/limit patent scope within a portfolio, you need to be aware of the competive landscape. Many intermediaries have developed sophisticated algorithms to determine their course of action. With our patent search tools, you can quickly and easily execute strategy based on our sophisticated algorithms. Understanding patent analytics just got easier.

Let IPstreet.com help you keep your patent portfolio organized. Organize your patents into groups, related to your product offerings. Identify each patent into a few tiers, where top-tiered patents are of higher commercial importance. This internal ranking can help identify which patents to maintain both domestically and internationally. Additionally, such a simple ranking will allow for establishing strategic enforcement guidelines. Resources are limited, so knowledge to identify which patents are most important can result in better utilization of resources. Using our patent search tools, you can better understand the value of a patent and analytics behind it.

In order to be SOX compliant, it is imperative that you keep track of your patent portfolio. A thorough IP audit requires organization. Ironically, companies will pay more for the procurement of patents than they will for organizing and managing IP portfolios. With IP Street, we can help you navigate your own IP landscape and quickly organize your portfolios. With our promise of ongoing innovation, we can further develop tools you need to make this organization possible.